- Conditions
- Bioequivalence
- Interventions
- Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
- Drug
- Lead sponsor
- Austarpharma, LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Edison, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- amantadine hydrochloride, oseltamivir phosphate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Influenza
- Interventions
- TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Influenza
- Interventions
- Oseltamivir Phosphate, ADS-8902
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 16
- States / cities
- San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
- Conditions
- Influenza
- Interventions
- Influenza Virus influenza A H3N2 strain
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Virus Diseases
- Interventions
- GSK1325756 (Danirixin), Placebo To Match GSK1325756, Oseltamivir Phosphate, Placebo To Match Oseltamivir Phosphate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more